Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Notes Payables (2021 - 2025)

Core Scientific's Notes Payables history spans 5 years, with the latest figure at $16.2 million for Q1 2025.

  • For Q1 2025, Notes Payables fell 30.51% year-over-year to $16.2 million; the TTM value through Mar 2025 reached $16.2 million, down 30.51%, while the annual FY2024 figure was $16.3 million, 86.9% down from the prior year.
  • Notes Payables for Q1 2025 was $16.2 million at Core Scientific, roughly flat from $16.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $977.6 million in Q3 2022 and bottomed at $16.2 million in Q1 2025.
  • The 5-year median for Notes Payables is $35.9 million (2022), against an average of $130.4 million.
  • The largest YoY upside for Notes Payables was 243.13% in 2023 against a maximum downside of 87.28% in 2023.
  • A 5-year view of Notes Payables shows it stood at $76.0 million in 2021, then tumbled by 52.31% to $36.2 million in 2022, then skyrocketed by 243.13% to $124.4 million in 2023, then tumbled by 86.9% to $16.3 million in 2024, then fell by 0.47% to $16.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Notes Payables are $16.2 million (Q1 2025), $16.3 million (Q4 2024), and $17.9 million (Q3 2024).